Lysosomal Storage Disorders (LSDs) present a unique challenge for pharmaceutical and biotech companies. With over 70 distinct types, each with varying symptoms and severity, identifying and reaching the right healthcare providers (HCPs) and patients can be like finding a needle in a haystack. Traditional methods often fall short, leading to wasted resources and missed opportunities.
The LSD Diagnostic Dilemma
LSDs are individually rare and often mimic other conditions, making diagnosis difficult. This diagnostic complexity is compounded by:
- Overlapping symptoms: LSDs can present with a wide range of symptoms, making it challenging to distinguish them from more common conditions.
- Limited HCP awareness: Many HCPs may not be familiar with the full spectrum of LSDs, leading to misdiagnosis or delayed diagnosis.
- Testing limitations: Access to specialized diagnostic testing, such as genetic testing, can be limited, further hindering accurate diagnosis.
Prognos Health: Revolutionizing LSD Commercialization
Prognos Health offers a game-changing solution for commercial teams in the LSD space. By leveraging real-world data (RWD) and advanced analytics, Prognos empowers commercial teams to:
- Pinpoint HCPs treating LSD patients: Identify HCPs with the highest concentration of LSD patients, enabling targeted engagement and resource allocation.
- Access real-time diagnostic insights: Gain access to comprehensive diagnostic data, including genetic testing and clinical laboratory results, to identify confirmed LSD patients and understand their specific disease subtypes.
- Segment and target with precision: Build highly specific cohorts based on diagnosis type, demographics, treatment history, and other key criteria, allowing for tailored messaging and engagement strategies.
- Optimize field force effectiveness: Equip field teams with actionable insights to prioritize HCP engagements and maximize impact.
Key Prognos Features for LSD Commercialization
- Unparalleled data partnerships: Prognos partners with leading specialty genetic testing labs and national reference labs, providing access to the most comprehensive diagnostic data available. Prognos Health is best able to support Gaucher disease, Fabry disease, Tay-Sachs disease, Niemann-Pick disease, Krabbe disease, Pompe disease, Mucopolysaccharidosis Type 1, and similar.
- Real-time patient identification: Identify newly diagnosed LSD patients and their associated HCPs in real-time, enabling proactive engagement.
- Granular cohort building: Create highly targeted cohorts based on inheritance patterns, specialties, test types, demographics, and more.
- Claims integration: Understand therapy status and identify potential treatment opportunities.
Benefits for Commercial Teams
- Improved HCP targeting: Focus resources on the HCPs most likely to treat LSD patients.
- Enhanced patient identification: Identify and reach the right patients at the right time.
- Increased sales force effectiveness: Drive more impactful HCP engagements and improve sales performance.
- Optimized marketing campaigns: Develop targeted marketing campaigns that resonate with HCPs and patients.
Prognos Health is transforming how pharmaceutical and biotech companies approach LSD commercialization. By providing access to real-time diagnostic insights and precise targeting capabilities, Prognos empowers commercial teams to maximize their impact and improve patient outcomes.
Ready to revolutionize your LSD commercialization strategy? Contact Prognos Health today to learn more.